Marshall Wace, LLP Viridian Therapeutics, Inc.\De Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Marshall Wace, LLP holds 684,799 shares of VRDN stock, worth $14.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

684,799

Previous 72,974 838.42%

Holding current value

$14.8 Million

Previous $949,000 1541.62%

% of portfolio

0.02%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$12.16 - $23.33 $7.44 Million - $14.3 Million	611,825 Added 838.42%	684,799 $15.6 Million
Q2 2024 Aug 14, 2024	SELL	$11.6 - $17.26 $66,433 - $98,848	-5,727 Reduced 7.28%	72,974 $949,000
Q1 2024 May 15, 2024	SELL	$17.09 - $23.82 $3.8 Million - $5.3 Million	-222,588 Reduced 73.88%	78,701 $1.38 Million
Q4 2023 Feb 14, 2024	SELL	$11.12 - $22.5 $7.35 Million - $14.9 Million	-661,204 Reduced 68.7%	301,289 $6.56 Million
Q3 2023 Nov 14, 2023	BUY	$15.16 - $24.7 $4.72 Million - $7.69 Million	311,314 Added 47.81%	962,493 $14.8 Million
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $493,357 - $648,556	21,859 Added 3.47%	651,179 $15.5 Million
Q1 2023 May 15, 2023	BUY	$25.04 - $37.6 $447,289 - $671,648	17,863 Added 2.92%	629,320 $16 Million
Q4 2022 Feb 14, 2023	BUY	$18.78 - $29.74 $52,490 - $83,123	2,795 Added 0.46%	611,457 $17.9 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $1.75 Million - $4.18 Million	163,863 Added 36.84%	608,662 $12.5 Million
Q2 2022 Aug 15, 2022	BUY	$9.55 - $19.0 $4.08 Million - $8.12 Million	427,236 Added 2432.59%	444,799 $5.15 Million
Q1 2022 May 16, 2022	SELL	$16.79 - $20.88 $1.19 Million - $1.48 Million	-70,842 Reduced 80.13%	17,563 $326,000
Q4 2021 Feb 14, 2022	BUY	$15.65 - $21.5 $1.38 Million - $1.9 Million	88,405 New	88,405 $1.75 Million

Others Institutions Holding VRDN

# of Institutions

179

Shares Held

76.8M

Call Options Held

581K

Put Options Held

439K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $859M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Viridian Therapeutics, Inc.\De Transaction History